Last €27.23 EUR
Change Today +0.049 / 0.18%
Volume 100.0
MYD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:22 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYD) Snapshot

Open
€27.20
Previous Close
€27.18
Day High
€27.23
Day Low
€27.20
52 Week High
04/4/14 - €30.50
52 Week Low
12/30/13 - €15.03
Market Cap
2.0B
Average Volume 10 Days
91.0
EPS TTM
--
Shares Outstanding
72.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYRIAD GENETICS INC (MYD)

myriad genetics inc (MYD) Related Businessweek News

View More BusinessWeek News

myriad genetics inc (MYD) Details

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests in the United States and internationally. It operates through three segments: Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. The company’s molecular diagnostic tests are designed to analyze genes, diagnose disease, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; EndoPredict medicine test for breast cancer; and MELARIS predictive medicine test for hereditary melanoma. The company also provides myPath Melanoma diagnostic medicine test for melanoma; myPlan lung cancer, a prognostic medicine test for lung cancer; myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and Vectra DA, a personalized medicine test for rheumatoid arthritis. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. The company was founded in 1991 and is headquartered in Salt Lake, Utah.

1,649 Employees
Last Reported Date: 08/13/14
Founded in 1991

myriad genetics inc (MYD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $956.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $786.9K
President of Myriad Genetic Laboratories Inc
Total Annual Compensation: $1.1M
Executive Vice President, General Counsel and...
Total Annual Compensation: $716.9K
Chief Scientific Officer
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

myriad genetics inc (MYD) Key Developments

Myriad Genetics Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2014; Provides Earnings Guidance for the Year 2015

Myriad Genetics Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended June 30, 2014. For the quarter, the company reported total revenues of $188,765,000 against $174,116,000 a year ago. Operating income was $53,251,000 against $65,917,000 a year ago. Income before income taxes was $52,550,000 against $67,227,000 a year ago. Net income was $33,629,000 or $0.43 per diluted share against $44,074,000 or $0.53 per diluted share a year ago. Non-GAAP operating income was $56,235,000 against $66,111,000 a year ago. Non-GAAP net income was $37,128,000 or $0.48 per diluted share against $44,268,000 or $0.54 per diluted share a year ago. GAAP cash flow from operations was $40,933,000 against $63,000,000 a year ago. Capital expenditures were $4,618,000 against $2,791,000 a year ago. For the six months, the company reported total revenues of $778,216,000 against $613,165,000 a year ago. Operating income was $274,442,000 against $228,002,000 a year ago. Income before income taxes was $277,865,000 against $233,276,000 a year ago. Net income was $176,225,000 or $2.25 per diluted share against $147,139,000 or $1.77 per diluted share a year ago. Non-GAAP operating income was $291,685,000 against $228,779,000 a year ago. Non-GAAP net income was $189,646,000 or $2.43 per diluted share against $147,916,000 or $1.78 per diluted share a year ago. GAAP cash flow from operations was $190,213,000 against $173,866,000 a year ago. Capital expenditures were $14,271,000 against $11,373,000 a year ago. The company is guiding toward fiscal year 2015 total revenue of $800 to $820 million and adjusted diluted earnings per share of $1.90 to $2.00. Adjusted EPS excludes approximately $12 million in anticipated non-cash amortization charges related to the acquisition of Crescendo Bioscience, which translates to GAAP EPS guidance of $1.75 to $1.85. GAAP diluted net income per share to be $1.75 to $1.85.

Myriad Genetics Inc. to Report Q4, 2014 Results on Aug 12, 2014

Myriad Genetics Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Aug 12, 2014

Myriad Genetics Inc., Q4 2014 Earnings Call, Aug 12, 2014

Myriad Genetics Inc., Q4 2014 Earnings Call, Aug 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYD:GR €27.23 EUR +0.049

MYD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $18.97 USD +0.02
Bio-Reference Laboratories Inc $29.05 USD -0.55
Foundation Medicine Inc $23.27 USD +0.14
Genomic Health Inc $29.72 USD +0.60
Imperial Innovations Group PLC 465.00 GBp +5.50
View Industry Companies
 

Industry Analysis

MYD

Industry Average

Valuation MYD Industry Range
Price/Earnings 16.0x
Price/Sales 3.4x
Price/Book 3.7x
Price/Cash Flow 14.9x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.